Skip to main content
Premium Trial:

Request an Annual Quote

Applied Proteomics, ALS TDI Collaborating on Markers

NEW YORK (GenomeWeb News) – Applied Proteomics and The ALS Therapy Development Institute (ALS TDI) are collaborating to validate protein biomarkers for tracking the progression of, and developing therapies for, amyotrophic lateral sclerosis, also called Lou Gehrig's disease.

"The absence of viable diagnostic and therapeutic tools for managing and treating ALS is tragic," John Blume, CSO at Applied Proteomics, said in a statement.

Blume said that his firm is "combining our systems engineering approach for proteomics-based biomarker discovery with their unique collection of focus, research talents, disease models, and experimental data."

ALS TDI has already provided Applied Proteomics with mouse spinal cords that serve as a preclinical model for ALS, and the firm has used mass spectrometry to isolate and study and quantify changes in protein expression. Cambridge, Mass.-based ALS TDI has been comparing the data from those studies to a proprietary RNA expression database.

The company said that the efforts are "a crucial first step in order to determine the reliability of protein markers identified through the process."

Currently, there are no homogenous protein biomarkers for ALS, the partners noted.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.